M-J. Ahn

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

Hepatocellular carcinoma

Osimertinib: First Global Approval

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

The biology and management of non-small cell lung cancer

Guillain-Barré syndrome

Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Current and future perspectives of liquid biopsies in genomics-driven oncology

Delivery technologies for cancer immunotherapy

Lung cancer: current therapies and new targeted treatments

Sex and gender: modifiers of health, disease, and medicine

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

Frameshift events predict anti–PD-1/L1 response in head and neck cancer

Liquid biopsies come of age: towards implementation of circulating tumour DNA

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view

Non-small-cell lung cancer

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Immune checkpoint inhibitors: new strategies to checkmate cancer

Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer

Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study

Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC

Levels of Egfr T790M in Plasma Dna As a Predictive Biomarker for Response to Azd9291, a Mutant-Selective Egfr Kinase Inhibitor